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1. Introduction
Numerous epidemiological studies have reported that metformin, a well-known and widely
used anti-diabetic drug, may provide protective benefits in decreasing pancreatic cancer risk
among the diabetic population. Following a brief introduction regarding metformin’s history
and pharmacological properties, this book chapter presents epidemiological findings showing
how metformin is associated with protection against pancreatic cancer. We also introduce the
anti-cancer effects of metformin through AMPK-independent and AMPK-dependent manners
[1-6]. These mechanisms include its inhibitory effects on the insulin growth factor-1 (IGF-1),
G protein-coupled receptor (GPCR) and mTORC1 signaling pathways [3-10]. We then discuss
the metabolic effects of metformin in cancer. For example, metformin has been shown to inhibit
glycolysis in various cancer cell lines [11-13]. Metformin is a known inhibitor of complex I of
the electron transport chain [14-18], potentially limiting the intact oxidative respiration
capabilities of the cancer cell. We also discuss in depth the anti-cancer mechanisms of action
of metformin in the context of lipid metabolism as reported in numerous models. These include
metformin’s ability to increase fatty acid β-oxidation in adipocytes [19] and its ability to inhibit
hepatic lipogenesis [2]. As shown by numerous studies [20-23], metformin also possesses anti-
lipogenic properties, potentially limiting this critical metabolic pathway that confers cancer
pancreatic cell survival advantage.
We provide preclinical and clinical evidences of the potential utility of metformin in pancreatic
cancer. For example, a very recent report has shown tumor growth inhibition in vitro and in
vivo by metformin through down-regulation of Sp (specificity protein) transcription factors
and consequent down-regulation of the Sp-regulated genes.[24]. Metformin has been also
shown to impair tumor development in pancreatic cancer in xenografts models [25]. Finally,
we also explore the role of lipid metabolism in the context-specific ability of metformin to act
as a chemopreventive/therapeutic agent. As early as 2001, it has been reported that metformin
significantly impairs the formation of pancreatic lesions induced by the pancreatic carcinogen
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N-nitrosobis-(2-oxopropyl)amine in hamsters fed a high fat diet [26]. We will argue that the
in order for metformin to exert its anti-cancer properties, consideration of the genetic and
metabolic status of the model system is critical.
We conclude this chapter by discussing our most recent findings that show how metformin
inhibits glucose-derived fatty acid synthesis in the context of available acetyl-CoA and the
presence of K-ras mutation in pancreatic cancer cells in the context of obesity, the metabolic
syndrome and diabetes [21]. These results strongly suggest that metformin, being an anti-
lipogenic drug, may be useful when combined with lipid lowering and chemotherapeutic
agents. Finally, because up-regulation of fatty acid synthase (FAS), the enzyme that catalyzes
the terminal step in palmitate synthesis, is associated with increased resistance to gemcitabine
and radiation treatments in human pancreatic cancer tissues [27], we argue that the use of
metformin could synergize with these treatments.
However, an important question remains on whether or not metformin really has chemopre‐
ventive and/or therapeutic use for pancreatic cancer. This chapter argues that metformin does
have anti-cancer properties by examining numerous experimental studies on metformin’s
potential mechanisms of action along with the metabolic and genetic context by which
metformin may act as an anti-cancer drug.
2. The history behind metformin
Galega officinalis (also known as the French lilac or Goat’s Rue) is a plant that has been used for
the treatment of diabetes mellitus in traditional medicine for centuries. At the end of the 19th
century, guanidine compounds were discovered in Galega extracts (Figure 1). Shortly after, in
1918 animal studies showed that these compounds lowered blood glucose levels [28]. How‐
ever, guanidines are fairly toxic. Following this discovery, some less toxic derivatives, named
synthalin A and synthalin B (Figure 1), were synthesized based on the structure of galegine
and used for diabetes treatment under the marketed name of Synthalin in the 1940s. The
discovery of insulin overshadowed the use and further development of synthalin compounds
and they were forgotten for the next several decades. When chemists found that they could
also make the guanidine compounds more tolerable by bonding two guanidines together,
forming a biguanide, interest in these molecules was regained and attention was focused on
metformin, phenformin and buformin (Figure 1). Finally, the interest in metformin, synthe‐
sized by K. Slotta, was further renewed in the late 1950s after several reports that it could
reduce blood sugar levels in people. The French physician Jean Sterne published the first
clinical trial of metformin as a treatment for diabetes in 1957 [29].
3. Synthesis, structure and pharmacology of metformin
Synthesis: Metformin is synthesized by equimolar fusion of hydrochloric dimethylamine and
dicyandinamide at 130-150°C for 0.5 to 2 hours [30].
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Figure 2. Synthesis of N,N’-dimethyl biguanide.
Structure: Metformin is globally charged positively and does not or poorly permeates the
plasma membrane. The structure was represented in a wrong tautomeric form until it was
corrected in 2005 by a group of chemists from India [31]. Metformin is given to patients as a
Figure 1. Structures of guanidine and biguanides.
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hydrochloride from. Several studies have demonstrated an affinity of biguanides for phos‐
pholipids at the plasma membrane [32] as well as some protein binding [33]. The interaction
of the biguanide with the polar head group of phospholipids induces a diminution of the
plasma membrane fluidity leading to the rigidification of the plasma membrane [32]. However,
this reduction of the fluidity has not been reproduced by Wiernsperger and collaborators [33]
who showed an increase in fluidity of red blood cells membranes.
Metformin has an oral bioavailability of 50-60% under fasting conditions and the peak plasma
concentration is reached within a couple of hours. The plasma protein binding is negligible.
Metformin is not metabolized but it is accumulated in tissues such as the liver, the kidneys,
the salivary glands and the gastrointestinal tract [34]. Eighty percent of the elimination of
metformin occurs by the urinary tract. The average elimination half-life in plasma is 6.2 hours.
The half-life of biguanides is approximately 2 hours [34]. Interestingly, metformin is distrib‐
uted to (and appears to accumulate in) red blood cells with a much longer elimination half-
life: 17.6 hours.
4. Chemopreventive properties of metformin
Numerous observational studies show that metformin use, when compared against other
diabetic agents such as insulin and sulfonylureas, decreases cancer risk and overall cancer
mortality among the diabetic population. These protective associations have been reported
across different cancer types and among various diabetic populations.
Table 1A summarizes epidemiological studies that show pancreatic cancer risk and cancer
mortality associated with metformin use while Table 1B presents observational studies and
clinical trials on overall cancer risk and mortality in relation to metformin use. While some
studies show a reduction in pancreatic cancer [35-39] and overall cancer risk [37, 39-45] among
diabetic metformin users, there are also studies that report no significant difference in cancer
risk among diabetics who take metformin compared to patients who take other anti-diabetic
treatments [36, 46-51]. These conflicting results may be explained by differences in the study
population, the confounding factors accounted for during statistical analysis and the selected
study design (e.g., cohort versus case-control). For example, patients who were prescribed
metformin may generally have better glucose control compared to those prescribed insulin
hence, the risk for future diseases such as cancer may be lower at baseline for metformin users
versus diabetics treated with other modalities. As shown in Tables 1A and 1B, different studies
account for different confounding factors which can largely influence the results of disease
risk calculations. There is no standardized procedure for the selection of which potential
confounding factors are to be included in a statistical model hence; this can lead to large
variations among observational study outcomes. Overall, although these epidemiological
studies are correlative in nature and hence, cannot establish causality between metformin use
and cancer risk and mortality, they provide a biological basis to further explore whether
metformin possesses chemopreventive and/or chemotherapeutic properties.
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5. Chemotherapeutic properties of metformin
Experimental studies show that metformin possesses anti-cancer effects in various cancer
types. As the metabolic effects of metformin are discussed in the section “Metformin as an
Anti-lipogenic Drug,” figure 2 provides a summary of metformin’s effects exclusively on
cancer signaling pathways. Overall, we present metformin’s effects on cancer cells as AMPK-
dependent (pathways 2, 4, 5, 6 and 10) and independent (pathways 1, 3, 7- 9 and 11). Although
there is an overlap between cell signaling and metabolic alterations due to metformin treatment
(e.g., via ETC complex I and ATP production, AMPK/mTORC1 axis and metabolic control),
metformin’s anti-cancer effects can be grouped into: a) inhibition of ATP and ROS production,
b) inhibition of IRS-1/Akt/mTORC1 axis, c) anti-inflammatory effects, d) cell cycle arrest and
e) inhibition of general transcription factors.
First Author/
Year (reference) Location Design Outcome Comparison
Risk
(95% CI) Confounding Factors
Oliveria et al.,
2007 [46] United States Cohort
Pancreatic
cancer risk
Metformin vs no
Metformin
RR: 1.26
(0.80-1.99)
Age, gender,
gastrectomy, chronic
pancreatitis, deep
venous thrombosis,
dermatomyositis/
polymyositis,
alcoholism, hepatitis
B/C, history of polyps
Currie et al., 2009
[47] United Kingdom Cohort
Progression to
pancreatic
cancer
Sulfonylureas vs
Metformin
Metformin +
Sulfonylureas vs
Metformin
Insulin-based
therapies
HR: 4.95
(2.74-8.96)
HR: 0.38
(0.13-1.12)
HR: 4.63
(2.64-8.10)
Age, sex, smoking
status, diagnosis of a
previous cancer
Li et al., 2009 [35] United States Case-control
Pancreatic
cancer risk Metformin
OR: 0.38
(0.22-0.69)
Age, sex, race
smoking, alcohol, BMI,
family history of
cancer, diabetes
duration, use of insulin
Bodmer et al.,
2011 [36] United Kingdom
Case-
control
Pancreatic
cancer risk
Metformin (both
sexes)
Metformin (females
only)
Sulfonylureas
Insulin
OR: 0.87
(0.59-1.29)
OR: 0.43
(0.23-0.80)
OR: 1.90
(1.32-2.74)
OR: 2.29
(1.34-3.92)
BMI, smoking, alcohol
consumption, diabetes
duration
Ferrara et al., 2011
[48] United States Cohort
Pancreatic
cancer risk
Metformin and
pioglitazone
HR: 1.2
(1.0-1.5)
Age, ever use of other
diabetes medications,
year of cohort entry,
sex, race/ethnicity,
income, current
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First Author/
Year (reference) Location Design Outcome Comparison
Risk
(95% CI) Confounding Factors
smoking, baseline
HbA1c, diabetes
duration, new
diabetes
diagnosis, creatinine,
and congestive heart
failure
Liao et al., 2011
[49] Taiwan Cohort
Pancreatic
cancer risk Metformin
HR: 0.85
(0.39-1.89) Crude/ Unadjusted
Lee et al., 2011
[37] Taiwan Cohort
Pancreatic
cancer risk
Metformin vs.
potential use of other
oral anti-
hyperglycemic
medications
HR: 0.15
(0.03-0.79)
Age, gender, other
oral anti-
hyperglycemic
medication, Charlson
comorbidity index
score, time-dependent
metformin use
Morden et al.,
2011 [50] United States Cohort
Pancreatic
cancer risk Metformin
HR: 1.25
(0.89-1.75)
Age category, race/
ethnicity, diabetes
complications, obesity
diagnosis, oral
estrogen use, Part D
low income subsidy (a
poverty indicator), 14
Charlson
comorbidities, and
tobacco exposure
diagnosis
Ruiter et al., 2012
[38] Netherlands Cohort
Pancreatic
cancer risk
Metformin vs.
sulfonylureas
HR: 0.73
(0.66-0.80)
Age at first oral
glucose-lowering drug
(OGLD) prescription,
sex, year in which the
first OGLD prescription
was dispensed,
number of unique
drugs used in the year,
number of
hospitalizations in the
year before the start of
OGLD
Sadeghi et al.,
2012 [52] United States Cohort
Median survival
in pancreatic
cancer,
prognostic
factors of
overall survival
in pancreatic
cancer
Metformin vs. Non-
metformin
Univariate Analysis:
Metformin
Multivariate Analysis:
Metformin
15.2 months
vs. 11.1
months (P =
0.009)
HR: 0.68
(0.52-0.89)
HR: 0.64
(0.48-0.86)
No significant
differences in BMI,
age, sex, race, diabetes
duration, disease
stage, tumor size,
performance status,
serum CA-19-9
between metformin
and non-metformin
group
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First Author/
Year (reference) Location Design Outcome Comparison
Risk
(95% CI) Confounding Factors
Nakai et al., 2013
[51] Japan Cohort
Prognostic
factors of
overall survival
in pancreatic
cancer
Univariate Analysis:
Biguanide
Sulfonylureas
Insulin
Thiazolidine-dione
HR: 0.61
(0.19-1.44)
HR: 0.60
(0.39-0.88)
HR: 0.83
(0.59-1.15)
HR: 0.19
(0.01-0.84)
Age (G65 or Q65 years
old), sex (male or
female), performance
status (PS; 0Y1 or
2Y3), primary tumor
size (G30 or Q30 mm),
distant metastasis (yes
or no), body mass
index (G22 or Q22 kg/
m2), chemotherapy
(combination therapy
with gemcitabine and
S-1 vs others), DM (yes
or no), insulin (yes or
no), sulfonylurea (yes
or no), biguanide (yes
or no), thiazolidine
(yes or no),
hypertension (yes or
no), ACEI or ARB (yes
or no), Ca-blocker (yes
or no), A-blocker (yes
or no), and statin (yes
or no)
Singh et al., 2013
[53] Various
Meta-
analysis
Pancreatic
cancer risk Metformin use
OR:
0.76
(0.57-1.03)
Zhang et al., 2013
[39] Various
Meta-
analysis
Cancer
incidence and
mortality
Metformin (and in
combination with
other drugs) vs. non-
users
SRR: Incidence
0.54
(0.35-0.83)
Mortality
0.64
(0.48-0.86)
(a)
Bold type under “Risk” column indicates statistical significance using 95% confidence interval. HR, hazard ratio; OR, odds ratio,
SRR, summary relative risk.
First Author/
Year Location Design Outcome Comparison
Relative Risk
(95% CI)
Confounding Factors
Accounted for
Evans et al., 2005
[41] Scotland
Case-
control
Cancer
incidence
Metformin vs. no
metformin
OR: 0.77
(0.64-0.92)
Smoking, body mass
index, blood pressure,
and postcode rank for
material deprivation
Libby et al., 2009
[40] Scotland
Nested
case-
control
Cancer deaths Metformin vs. nometformin
HR: 0.63
(0.53-0.75)
Sex, age, BMI, A1C,
deprivation, smoking,
other drug use
Monami et al.,
2009 [42] Italy
Case-
control
Cancer
incidence
36 mo metformin vs
no metformin
OR: 0.28
(0.13-0.57)
Concomitant
therapies, exposure to
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First Author/
Year (reference) Location Design Outcome Comparison
Risk
(95% CI) Confounding Factors
metformin and
gliclazide
Bowker et al.,
2010 [44] Canada Cohort Cancer death
Metformin vs.
sulfonylurea
HR: 0.80
(0.65-0.98)
Age, sex and chronic
disease score
Home et al., 2010
[54] Various
Randomize
d control
trials
Cancer
incidence
Metformin vs.
rosiglitazone
Metformin vs.
glibenclamide
Metformin +
sulfonylurea vs.
Rosiglitazone +
sulfonylurea
HR: 0.92
(0.63-1.35)
HR: 0.78
(0.53-1.14)
HR: 1.22
(0.86-1.74)
Not reported
Landman et al.,
2010 [45] Netherlands Cohort
Cancer
mortality
Metformin vs. no
metformin
HR: 0.43
(0.23-0.80)
Smoking (yes or no),
age, sex, diabetes
duration, A1C, serum
creatinine, BMI, blood
pressure, total
cholesterol–to–HDL
ratio, albuminuria,
insulin use,
sulfonylurea use, and
macrovascular
complications (yes or
no)
Lee et al., 2011
[37] Taiwan Cohort
Cancer
incidence
Metformin vs. no
metformin
HR: 0.12
(0.08-0.19)
age, gender, other oral
anti-hyperglycemic
medication usage, CCI
score and dose and
duration of metformin
exposure
Monami et al.,
2011 [43] Italy
Case-
control
Cancer
incidence
Metformin vs. no
metformin in patients
under insulin
treatment,
OR: 0.46
(0.25-0.85)
Charlson comorbidity
score (CCS), glargine
mean daily dose
(MDD), and total MDD
of insulin
Zhang et al., 2013
[39] Various
Meta-
analysis
Cancer
incidence and
mortality
Metformin (and in
combination with
other drugs) vs. non-
users
SRR: Incidence
0.73
(0.64-0.83)
Mortality
0.82
(0.76-0.89
(b)
Bold type under “Risk” column indicates statistical significance using 95% confidence interval. HR, hazard ratio; OR, odds ratio,
SRR, summary relative risk.
Table 1. A. Human Studies on Pancreatic Cancer Risk and Mortality with Metformin Use Among Diabetics, B. Human
Studies on Overall Cancer Risk and Mortality with Metformin Use Among Diabetics
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1] Metformin is a known inhibitor of complex I of the electron transport chain (ETC) [14, 15]. 2) The resulting decrease
in adenosine triphosphate (ATP) production and increase in adenosine monophosphate (AMP) levels activate the kin‐
ase AMP-activated protein kinase (AMPK), a regulator of cellular energy status. Besides inhibition of energy-consum‐
ing biosynthetic processes (e.g., lipid synthesis and gluconeogenesis) and up-regulation of energy-generating
catabolic metabolic pathways (e.g., β-oxidation of fatty acids and glycolysis), AMPK also signals to numerous proteins
involved in cell survival, senescence, autophagy and death. For example, both high AMP and adenosine diphosphate
(ADP) levels (from ETC complex I inhibition) is permissive for AMPK activation. AMP promotes AMPK phosphorylation
at its catalytic α-subunit (Thr-172) by its upstream kinases liver kinase B1 (LKB1) and calcium/calmodulin-dependent
protein kinase kinase-beta (CaMKKβ), its allosteric activation and prevents dephosphorylation by protein phosphatase
type 2a (PP2a) and protein type 2c (PP2c) phosphatases [55-57]. ADP also protects AMPK from dephosphorylation
[58]. 3) The metformin-induced decline in endogenous reactive oxygen species (ROS) levels has been implicated to be
involved in cancer risk reduction owing to its ability to reduce ROS-induced DNA damage [59]. 4) AMPK has also been
shown to activate the tumor suppressor protein 53 (p53) (Ser-15) in inducing cancer cell cycle arrest and senescence
[60]. The reversible arrows between p53 and pAMPK indicate that p53 has been shown to increase AMPK activity
which, ultimately leads to mammalian target of rapamycin (mTOR) inhibition in vitro [61]. 5) Metformin has been
shown to cause a G0/G1 cell cycle arrest by decreasing the expression of cyclin D1 and preventing the phosphoryla‐
tion of pRb and hence, its inactivation [62]. 6) Metformin-induced AMPK activation has been shown to phosphorylate
insulin receptor substrate-1 (IRS-1) at Ser-794 which results in decreased recruitment of the p85 subunit of phosphoi‐
nositide-3-kinase (PI3K), thus, impairing the insulin-like growth factor (IGF)-stimulated PI3K/protein kinase B/ mam‐
malian target of rapamycin complex 1 (PI3K/Akt/mTORC1) signaling pathway [63]. Metformin has also been shown to
inhibit the crosstalk between the insulin/IGF receptor and G protein-coupled receptor (GPCR) signaling, resulting in
the inhibition of mTORC1 [4, 5]. 7) Biguanides are implicated in the inhibition of the Rag-dependent mTORC1 signal‐
ing [8], by preventing the co-localization of mTORC1 with its activator Ras homolog enriched in brain (Rheb). Rags are
GTPases comprised of four proteins RagA, RagB, RagC and RagD that heterodimerize to activate mTORC1 upon amino
acid stimulation [10]. Rags bind to the Ragulator complex made up of mitogen-activated protein kinase scaffold pro‐
tein 1 (MP1), p14 and p18 trimeric proteins, localizing mTORC1 from the perinulcear compartment (where Rheb is lo‐
cated) into the cytoplasm, preventing Rheb activation of mTORC1 [64]. 8) Metformin also increases the expression of
the mTOR inhibitor, regulated in development and DNA damage responses (REDD1), consequently down-regulating
mTOR signaling [65]. 9) In human monocytes, metformin prevents lipopolysaccharide (LPS) and oxidized low density
lipoprotein (LDL)-induced tumor necrosis factor (TNF) production at micromolar concentrations [66]. 10) Activation
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and phosphorylation of AMPK is dependent on the serine-threonine kinase, ataxia telangiectasia mutated (ATM), a
checkpoint that responds to double-strand breaks and oxidative stress by activating the DNA damage response involv‐
ing numerous downstream targets such as p53, checkpoint kinase 2 (Chk2), breast cancer 1 (BRCA1), Fanconi anemia,
complementation group 2 (FANCD2), Nijmegen breakage syndrome 1 (Nbs1), p53 upregulated modulator of apopto‐
sis (Puma) - Phorbol-12-myristate-13-acetate-induced protein 1 (Noxa) and BCL2-associated X protein (Bax) [67, 68]
thus, preventing further DNA insult. 11) Metformin induces nuclear degradation and decreased expression of Sp pro‐
teins, transcription factors for genes involved in cell proliferation (cyclin D1), metabolism (FAS), apoptosis ((B-cell lym‐
phoma 2 (bcl-2) and survivin)) and angiogenesis ((vascular endothelial growth factor (VEGF) and its receptor VEGFR1))
[24].
Figure 3. Metformin impairs signaling molecules for cancer survival.
6. Overall physiological and cellular effects of metformin in cancer models
Contrary to sulfonylureas, which act at the level of the pancreatic secretion of insulin, bigua‐
nides act at the level of sensitivity of the target tissues for insulin. Moreover, the biguanides
can reduce the hyperglycemia without leading to incidental hypoglycemia. Hence, the term
“anti-glycemic” agent was coined for metformin.
In the late 90s, amongst many studies published on the cellular effects of metformin, we
showed that metformin is able to modulate the insulin receptor (IR) in cholesterol (chol)-
treated human hepatoma cells, HepG2 [69]. In that study, we used a cellular model in which
insulin sensitivity was altered by supplementing the culture medium of HepG2 cells with a
derivative of CHOL, cholesteryl hemisuccinate (CHS) [70, 71]. Overall, metformin did not
affect IR phosphorylation in control cells. However, metformin affected IR autophosphoryla‐
tion in CHS-treated cells. At 1 and 5 min of insulin stimulation, metformin increased IR
phosphorylation in these cells, restoring IR phosphorylation in CHS-treated cells towards
control levels. As mentioned earlier, metformin is a charged biguanide, requiring cell surface
transport protein for its influx [72] and exhibits membrane effects as well as cellular effects [73].
Pertinent to our early work, recent studies from Algire et al. [74] demonstrated that a high
energy diet promotes tumor growth and that metformin decreases tumor volume only in high-
energy fed animals. The authors suggest that, “the inhibitory effect of metformin on tumor growth
was restricted to animals on the high-energy diet. These results suggested that any benefits of this drug
in reducing cancer aggressiveness may be restricted to a metabolically defined subset of cancer pa‐
tients.” [74].
After nearly two decades of research and approval of metformin by the FDA in 1994, the target
of the compound has yet to be identified. Arguably, as mentioned above, metformin is a
charged biguanide, requiring cell surface transport protein for its influx [75] and exhibits
membrane effects as well as cellular effects [73]. While Algire et al found that the anti-tumor
effect of metformin was limited in animals on high-energy diets using in vivo models of lung
and colorectal xenografts [76]; very recently, the work from Rozengurt and Eibl (from UCLA)
demonstrates a strong tumor growth delay effect of metformin in pancreatic cancer xenograft
models [5]. However, the doses used (>200mg/kg, i.p.) may not be clinically relevant. The
ongoing debate on metformin dosages in animal models and human clinical trials has yet to
define clearly the anti-diabetic dose versus the anti-cancer dose as well as a preventive versus
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a treatment dosage. The usual anti-diabetic dose of metformin is 500 - 1250 mg PO BID.
Maximum recommended dose in patients with diabetes in 1250 mg PO BID. There seem to be
some difference in data regarding prevention or actual treatment of cancer with metformin.
The typical serum concentration from 1000- 2000 mg/day of metformin in diabetic patients is
about 0.5 - 2 mg/L. The retrospective data so far have primarily looked at these doses and have
shown that metformin prevents some cancers (including pancreatic cancer) [52, 77]. If we look
at data regarding treatment of pancreatic cancer with metformin, it is different in terms of
dosing. The pre-clinical data show that much higher doses are used (10-100 times the clinical
used doses). If we look at data in humans using metformin for treatment of cancers, it shows
some benefit at clinically used doses but it certainly is not as impressive as pre-clinical high
dose metformin [78-80]. We did not find any ongoing human study using very high doses
(beyond 3000 mg/day) primarily to treat cancers. Further studies need to be performed
addressing this issue within the same animal model or within a similar patient population.
Finally, the fact that metformin prevents tumor development and growth in nude mice [5],
supports a potential priming effect of metformin on the host potentially limiting the availability
of ‘onco’ metabolites for which the tumor is ‘addicted’. These types of studies investigating
the processes of carcinogenesis, may address important gaps in current knowledge regarding
the role of tumor metabolism in drug response. We strongly believe that mechanistic insight
on these issues will have exceptionally high impact and potentially re-shape current paradigms
about anti-metabolic drugs, pancreatic cancer treatment and personalized medicine. Indeed,
we speculate that the efficacy of metformin – and possibly drugs with similar mechanism –
depends on the metabolic context in which the tumor exists. This is potentially, a paradigm-
changing concept as it suggests that host/tissue metabolic factors play a role in tumor condi‐
tioning and influence treatment response; a hypothesis that has not previously been considered
in the clinical evaluation of metformin.
6.1. Metformin as a glucose lowering drug
Metformin works by decreasing hepatic gluconeogenesis [81], activating insulin receptor
tyrosine phosphorylation [82], decreasing intestinal glucose absorption and increasing skeletal
and adipose tissue glucose uptake [82]. One mechanistic study conducted in mice demon‐
strates that metformin (250 mg/kg/day for three consecutive days) increases the association of
the glycolytic enzymes hexokinase to the mitochondria and phosphofuctokinase to F-actin in
mice hearts [83]. These associations result in their activation and up-regulation in glycolysis,
increasing cardiac glucose utilization which may partly explain the cardio protective effects
of the drug [84, 85]. Since 1995, metformin has been a widely prescribed glucose lowering agent
in the United States for type 2 diabetic and polycystic ovary syndrome patients. It is a well-
tolerated drug with lactic acidosis as a reported serious side effect [86]. However, the link
between lactic acidosis and metformin use has recently been questioned [87].
6.2. Metformin as an anti-lipogenic drug
Dating back to the 1920’s, Otto Warburg published his observations on the metabolic aberra‐
tions of cancer cells. In the seminal paper entitled “The Metabolism of Tumors in the Body,”
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Warburg and colleagues showed the absence of lactic acid accumulation in the blood of normal
animals (no cancer) [88]. Whereas, animals with tumors accrued greater concentration of lactic
acid in venous compared to arterial blood as well as in the tumor cavity, indicating the
formation of lactic acid from glucose fermentation as blood goes through the tumor [88].
Metformin inhibits the gene expression of carnitine palmitoyltransferase 1 (CPT1), a mitochondrial enzyme that is the
rate-limiting step in long-chain fatty acid β-oxidation. CPT1 catalyzes the transfer of acyl-CoA to the carnitine hydroxyl
group, forming acyl-carnitine which is then transported into the mitochondrial matrix via translocase. Carnitine palmi‐
toyltransferase 2 (CPT2) catalyzes the formation of acyl-CoA from acyl-carnitine. Acyl-CoA then undergoes β-oxida‐
tion. Metformin prevents the nuclear activation of sterol-regulatory element-binding protein 1c isoform (SREBP-1c)
and SREBP-2 sterol-regulatory element-binding protein 2 isoform (SREBP-2), transcription factors that induce the ex‐
pression of enzymatic genes involved in fatty acid and cholesterol synthesis, respectively. Metformin decreases the ac‐
tivities of 3-hydroxy-3-methyl-glutaryl-CoA reductase (HMGCR) and acyl coenzyme A:cholesterol acyltransferase
(ACAT). HMGCR is the rate-limiting enzyme of the mevalonate pathway, that catalyzes the reduction of 3-hydroxy-3-
methylglutaryl-coenzyme A (HMGCoA) to mevalonate. The mevalonate pathway synthesizes isoprenoids and choles‐
terol. ACAT is an endoplasmic reticulum protein that catalyzes the formation of cholesterol esters from acyl-CoA and
cholesterol. Metformin decreases the gene expression of steroyl-CoA desaturase 1 (SCD1), the enzyme responsible for
desaturation of stearic acid (18:0) into oleic acid (18:1 n-9) and of palmitic acid (16:0) to palmitoleic acid (16:1 n-7).
MET decreases the protein expression of FAS, acetyl-CoA carboxylase (ACC) and ATP citrate lyase (ACLY), which are
enzymes involved in fatty acid synthesis.
Figure 4. Metformin inhibits key metabolic steps in lipogenesis.
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The reliance of cancer cells on glucose metabolism stems from their need to generate metab‐
olites and reducing equivalents that are used to support crucial biosynthetic reactions that
make lipids, nucleotides and amino acids. These biomolecules are rate-limiting for cell
proliferation and survival. Glycolysis yields glucose-6-phosphate that enters the oxidative arm
of the Pentose Phosphate Pathway (PPP). The oxidative PPP produces NADPH which,
together with acetyl-CoA, fuels lipid synthesis in the cytosol. The non-oxidative branch of the
PPP yields ribose-5-phosphate that is the precursor for nucleotides. In fact, as early as 1998, it
has been argued that the both PPP branches (but primarily the non-oxidative branch) serve to
produce ribose to sustain the increased needs of the cancer cell for DNA and RNA [89].
Fructose-6-phosphate and glyceraldehyde-3-phosphate are by-products of the glycolytic and
the non-oxidative pentose phosphate pathways, providing an intimate link between glucose
metabolism and nucleotide generation. Acetyl-CoA produced from the pyruvate dehydro‐
genase reaction enters the tricarboxylic acid (TCA) cycle in the mitochondria. Citrate can be
exported from the mitochondria into the cytosol and converted back to acetyl-CoA (catalyzed
by ATP citrate lyase) for lipid synthesis. Malate, an intermediate in the TCA cycle, can be
converted into pyruvate by malic enzyme with the production of NADPH, a reducing
equivalent that is used to generate reduced glutathione, allowing cancer cells greater tolerance
to free radical-induced damage [90]. Glutaminase catalyses the hydrolysis of the amine group
of glutamine to form glutamate and ammonia. Glutamate equilibrates with α-ketoglutarate
via glutamate dehydrogenase. In a process termed reductive carboxylation, glutamine-derived
citrate provides the acetyl-CoA for lipid synthesis and TCA cycle intermediates [91]. Hence,
the glutamine addiction of cancer cells is another mechanism by which the metabolism is
rewired to support biosynthesis [90, 91]. Please refer to Figure 3 for an integrated visual of
cancer metabolism.
Diabetes and cancer are both metabolic diseases. It is therefore, not surprising that the
mechanisms of action of metformin against type 2 diabetes and cancer include the drug’s
ability to alter critical metabolic circuits that lead to the normalization of blood glucose in
diabetes and the impairment of biosynthetic pathways in cancer cells. For example, it is well-
established that metformin is an inhibitor of complex I of the ETC. In 2000, two research groups
have independently shown that dimethylbiguanide selectively blocks complex I of the ETC
[14, 15]. In intact isolated hepatocytes, dimethylbiguanide has been reported to dose-depend‐
ently (0.1 to 10mM) inhibit oxygen consumption maximally at 20-30min [15]. The inhibition
of respiration only occurred when glutamate-malate (complex I substrates) were used as
substrates versus when succinate (complex II substrate)-rotenone or N, N, N’, N’-tetrameth‐
yl-1,4-phenylenediamine dihydrochloride (TMPD)-ascorbate (complex IV substrates) were
added during the assessment of oxygen uptake. It is interesting to note that El-Mir and
colleagues did not observe these changes when oxygen uptake experiments were performed
in digitonin-permeabilized hepatocytes or in isolated liver mitochondria [15]. This is in
contradiction to what Owen and others published when they showed that lower metformin
concentrations of 50 and 100 μM were able to significantly decrease state 3 respiration rate in
digitonin-permeabilized rat hepatoma cells [14]. Metformin has slow permeation properties
across the inner mitochondrial membrane [14] and longer incubation periods (30 min in the
El-Mir group versus 24-60 hours in the Owen group) may have eventually yielded comparable
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results. In support of the previous findings, recent reports confirm that metformin is a specific
inhibitor of the ETC complex I which leads to some impairment in mitochondrial function in
human-derived non-malignant and in cancer cells [16-18, 92, 93]. This potentially limits the
intact oxidative respiration capabilities of the cancer cell [16].
Besides inhibition of complex I and effects on glucose metabolism, numerous studies also show
metformin-induced metabolic changes in non-cancer and cancer cells. One of the most notable
effects of metformin is inhibition of lipogenesis, a metabolic pathway that is critical for a cancer
cell’s survival advantage. Under lipogenic conditions, surplus glucose in the cell is converted
to pyruvate via glycolysis in the cytoplasm. Pyruvate is converted to acetyl-CoA and trans‐
ported as citrate from the mitochondria into the cytoplasm. ATP citrate lyase (ACLY) converts
citrate back to acetyl-CoA. Acetyl-CoA carboxylase (ACC) catalyzes the carboxylation of
acetyl-CoA to malonyl-CoA in an ATP-dependent manner. Acetyl-CoA and malonyl-CoA are
then used as substrates for the production of palmitate by the seven enzymatic reactions
catalyzed by FAS. In cancer, de novo fatty acid (FA) synthesis is up-regulated mainly for
membrane production (usage of FA for phospholipids) and post-translational modification of
proteins [94]. ACLY, ACC and FAS expression and activity have been shown to be up-
regulated in cancers including pancreatic cancer. Thus, metabolic enzymes involved in FA
synthesis have emerged as therapeutic targets in cancer [94]. The effects of MET on energy
homeostasis in normal hepatocytes and breast and colon cancer cells have been characterized
by the blocked activation or expression of key lipid biosynthesis enzymes such as ACC, FAS,
HMGCR and enhanced expression of regulators of mitochondrial biogenesis, peroxisome
proliferator-activated receptor-gamma co-activator 1 (PGC-1) [1, 74, 95].
Suppression of anabolic pathways (metformin is anti-lipogenic) is in keeping with the expected
consequences of AMPK activation [1]. HMGCR may also play an important role in human
malignancies. Indeed, recent transcriptional profiling demonstrated that cholesterol and lipid
metabolisms are linked to cellular transformation [96]. Interestingly, high HMGCR mRNA
levels correlated with poor patient prognosis and reduced survival. The levels of additional
mevalonate (MVA) pathway genes were also significantly correlated with poor prognosis of
breast cancer patients, suggesting the entire pathway may be deregulated in these cases [97].
It is interesting to note that the metformin-induced inhibition of respiration is blocked by the
addition of palmitate in 3T3-L1 adipocytes [19]. Adipocytes treated with palmitate complexed
to albumin in the presence of carnitine had comparable oxygen consumption rates when
compared to control. These results indicate that the metformin-induced inhibition of respira‐
tion can be reversed by the addition of fatty acids, which led the authors to conclude that the
mechanism of action of metformin may be linked to fatty acid metabolism [19]. Although
indirect, this article presented a link between metformin and its effects on lipid metabolism or
vice versa.
The normoglycemic effects of metformin has also been attributed to its ability to prevent fatty
acid oxidation which decreases acetyl-CoA, ATP and reducing equivalents’ availability for
hepatic gluconeogenesis [98], an effect likely mediated by a reduction in the expression of the
carnitine palmitoyltransferase I gene [99] and eventually, a decrease in protein expression and
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activity of the enzyme resulting in impairment in long fatty acid chain transport from the
mitochondrial outer membrane into the matrix where β-oxidation takes place. Current
publications also render support to the lipid-inhibitory effects of metformin. Metformin (0.2
to 1.0 mM for 16 h) has been shown to activate AMPK and decrease the mRNA, nuclear
translocation and consequent activation via cleavage of the nuclear portion and the promoter
activity of SREBP-1c in rat hepatoma McA-RH7777 cells [22, 23]. The mRNA and nuclear
protein levels of SREBP-2 were also reduced after metformin treatment. This AMPK-mediated
suppression of SREBP-1c has also been reported to prevent lipogenesis in an insulin resistant
mouse model [20] and is consistent with a decrease in hepatic SREBP-1 expression in mice fed
a high fat (60% lipids) diet for 10 weeks and then metformin (0.48mg% of the diet) for another
six weeks [100]. Since SREBP-1c and SREBP-2 are transcription factors that promote the
expression of enzymatic genes involved in fatty acid and cholesterol synthesis, respectively
[101] we would expect diminished lipid synthesis as a biological endpoint of their down-
regulation. In accordance, MRC5 human fetal lung fibroblasts incubated for 72 h with met‐
formin (5 x 10-5 to 5 x 10-4 M) decreased 1-14acetate incorporation into sterols, fatty acids and
triglycerides compared to control, accompanied by a reduction in the activities of HMGCR
and ACAT, enzymes that catalyze the formation of mevalonic acid from HMGCoA and the
esterification of cholesterol, respectively [102]. Also, metformin has been shown to induce the
phosphorylation (Ser-351) of the nuclear receptor TR4 via AMPK, leading to decreased TR4
transactivation and a decrease in the gene expression of its target, steroyl-CoA desaturase 1
(SCD1) gene expression. SCD is an enzyme that catalyzes the synthesis of monounsaturated
fatty acids palmitoleic acid (16:1 n-7) and oleic acid (18:1 n-9) from saturated fatty acids
obtained from de novo lipogenesis or from the diet [103]. SCD1 has been shown to be associated
to numerous diseases including but not limited to obesity, hepatic steatosis, hypertriglyceri‐
demia, insulin resistance, low grade inflammation and bone fractures [103].
The role of SCD1 in cancer has been gaining more attention as a potential pharmacological
target in cancer interventions [104]. SCD is an endoplasmic reticulum-bound protein encoded
by the SCD1 and SCD5 genes in humans [105]. They are highly expressed in liver and adipose
tissue (SCD1) and in the brain and the pancreas (SCD5) [103]. Observational studies have
reported a positive association between saturation index (18:0 to 18:1 n-9 ratio used by
investigators as a marker for SCD activity) with cancer risk [106-110]. The first cDNA of human
SCD published in 1994 revealed that the mRNA levels of this enzyme were elevated in tissues
derived from esophageal carcinoma, colorectal cancer and hepatocellular adenoma [111]. Its
protein levels are highly expressed in SV40-transformed fibroblasts compared to their wild
type counterpart [112]. However, decreased transcript expression was reported in prostate
cancer when compared to normal epithelium [113]. These seemingly conflicting results may
reflect variation in expression depending on the tissue type or some malignancy-induced
metabolic changes in lipid synthesis and/or lipid profile which would overall guarantee cancer
cell survival advantage. Indeed, Moore and others speculated that the down-regulation of SCD
cDNA in prostate carcinoma may be due to: a) the need of the cancer cell to increase the levels
of palmitate which can be done by decreasing SCD activity, b) eliminate the SCD-induced
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down-regulation of lipid membrane rafts and c) down-regulate susceptibility of tumor cells
containing more unsaturated fatty acids to TNF-induced free radical attack [113]. Nevertheless,
knockdown of human SCD in transformed human fibroblasts resulted in decreased oleic acid
synthesis, lowered desaturation index profiles of the main polar lipids phosphatidylcholine
and phosphatidylethanolamine, and decreased de novo synthesis of 14C-labeled phospholipids,
cholesterol and cholesterol esters, free fatty acids and triacylglycerols [114]. Interestingly, there
was an inhibition in cellular proliferation and anchorage-independent growth in the SCD
knockdown cells [114]. Other studies confirm that SCD inhibition by chemical or genetic
manipulations resulted in inhibition of cancer cell proliferation and/or death [115-118]. Thus,
SCD appears to be involved in modulating lipid metabolism and signaling processes crucial
for cancer cell replication and anchorage-independent growth, effects are likely influenced by
the effects of SCD loss on membrane integrity [114].
In support of the anti-lipogenic effects of metformin, Bhalla and others [2] have reported that
metformin decreased the gene and protein expression of enzymes involved in fatty acid
synthesis namely, ACC, FAS and ACLY which was accompanied by a reduction in hepatic
triglycerides in a mouse model of hepatocellular cancer fed metformin at a dose of 250 mg/kg
for 24-36 weeks.
Obesity is a known risk factor for cancers of the pancreas, colon and rectum, esophagus, kidney,
prostate, breast, uterus and ovaries [119-123]. In order to recapitulate this condition in the
preclinical setting, animal models are fed high energy (HE), high fat (HF) diets to induce the
metabolic syndrome and/or obesity. In an in vivo model of colon carcinoma by Algire and
colleagues [124], metformin (50mg/kg/day for five weeks) significantly decreased tumor
volume only in mice fed the HF/HE diet. Of note, these concentrations are more likely to be
physiologically relevant to what a diabetic patient would have in their system. They also found
that metformin reduced the expression of SREBP-1 and one of its target enzymes, FAS,
regardless of the type of diet. Interestingly, a previous study from the same group using an in
vivo model of lung cancer back in 2008 showed that the tumor growth inhibitory impact of
metformin is exclusive to the mice under the HF/HE diet [76]. These two studies suggest that
metformin may retard cancer growth depending on a particular metabolic state of the
organism which in this case, is the abundance of circulating lipids from the HE/HF diet.
We recently found that the in vitro response to metformin depends on the level of intracellular
cholesterol synthesis of the tumor [125]. We were the first to demonstrate that a physiologically
relevant dose of metformin impairs glucose utilization in pancreatic cancer by inhibiting FAS
when cholesterol synthesis is limited. Specifically, we found that pancreatic cells that have a
K-ras mutation and that require de novo fatty acid (FA) synthesis for lipids ('lipogenic cells')
were unable to synthesize FA from acetyl-CoA in the presence of an inhibitor of cholesterol
synthesis and metformin. Our in vitro model shows that a physiologically relevant dose of
metformin (100 μM) using an acute treatment of 24 h decreases de novo lipid synthesis via the
FAS pathway in pancreatic adenocarcinoma only when: a) the glucose-derived acetyl-CoA is
made available for fatty acid synthesis by inhibition of cholesterol synthesis (addition of
exogenous cholesterol) and b) K-ras mutation is present [21]. As the fatty acid and cholesterol
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synthesis pathways utilize acetyl-CoA as a common substrate [126], the addition of cholesterol
(in the form of the more water-soluble cholesteryl hemisuccinate) inhibits the thiolase-
catalyzed cholesterol pathway and shifts the glucose-derived acetyl CoA- towards the acetyl-
CoA carboxylase-catalyzed fatty acid synthesis pathway. These effects are observed only in
MiaPaCa-2-cells, which harbor the GGT(Gly) to TGT(Cys) codon 12 K-ras mutation. Further,
non-lipogenic cancer cells harboring a K-rasG12C mutation [127] with suppressed cholesterol
synthesis were significantly more sensitive to the growth inhibiting effects of metformin than
tumor cells containing wild-type K-ras with normal cholesterol synthesis. These results are
consistent with expected modulation of AMPK [1] and/or mTOR [128].
Title Recruitment Results Conditions Interventions
Metformin Hydrochloride in
Treating Patients With
Pancreatic Cancer That Can be
Removed by Surgery
Not yet recruiting No ResultsAvailable
Pancreatic Cancer:
Stage IA
Stage IB
Stage IIA Stage IIB
Drug: metformin hydrochloride
Other: pharmacological study
Metformin Combined With
Chemotherapy for Pancreatic
Cancer
Recruiting No ResultsAvailable
Locally Advanced
Pancreatic Cancer/
Metastatic Pancreatic
Cancer
Drug: gemcitabine, erlotinib,
metformin, placebo
Metformin Plus Modified
FOLFOX 6 in Metastatic
Pancreatic Cancer
Recruiting No ResultsAvailable
Acinar Cell
Adenocarcinoma of the
Pancreas,
Duct Cell,
Adenocarcinoma of the
Pancreas,
Recurrent Pancreatic
Cancer,
Stage IV Pancreatic
Cancer
Drug: metformin hydrochloride,
oxaliplatin, leucovorin calcium,
fluorouracil
Other:
laboratory biomarker analysis
Combination Chemotherapy
With or Without Metformin
Hydrochloride in Treating
Patients With Metastatic
Pancreatic Cancer
Recruiting No ResultsAvailable Pancreatic Cancer
Drug: capecitabine, cisplatin,
epirubicin, gemcitabine,
metformin
Treatment of Patients With
Advanced Pancreatic Cancer
After Gemcitabine Failure
Recruiting No ResultsAvailable
Pancreatic
Adenocarcinoma
Advanced or Metastatic
Drug: paclitaxel, metformin
Gemcitabine+Nab-paclitaxel
and FOLFIRINOX and
Molecular Profiling for
Patients With Advanced
Pancreatic Cancer
Recruiting No ResultsAvailable
Stage IV Pancreatic
Cancer
Drug: Gemcitabine, nab-paclitaxel,
FOLFIRINOX, metformin
Genetic: Immunohistochemistry
(IHC) Analysis
Table 2. Ongoing Clinical Trials on Metformin and Pancreatic Cancer
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In summary, metformin’s anti-cancer properties rest on its ability to impair cancer cell
lipogenesis, a critical mechanism by which cancer cells maintain their survival advantage over
normal cells. Metformin is able to control lipogenesis through inhibition of the transcription
factors SREBP-1 and SREBP-2, inhibition of activities and/or expression of enzymes involved
in cholesterol and fatty acid synthesis. We have shown that metformin’s anti-cancer role is
effective in select metabolic phenotype and likely, a particulate cancer genotype. Thus, it is
important to understand the metabolic context by which metformin exerts anti-cancer effects
so that the correct patient population can be selected for therapeutic purposes.
7. Ongoing clinical trials on metformin as a chemotherapeutic drug for
pancreatic cancer
There is considerable interest in the anti-tumor action of the commonly used anti-diabetic drug
metformin for the treatment and management of patients with pancreatic cancer. Enthusiasm
for metformin has been significantly strengthened by in vitro and in vivo experimental findings
of potent anti-tumor activity of metformin at therapeutically safe doses. As a result, a number
of early phase trials are now being conducted to assess the efficacy of metformin in combination
with standard and experimental therapeutics in pancreatic cancer patients. Although there are
numerous studies that show the cancer preventive and cancer therapeutic actions of metformin
in preclinical models, there is a need to conduct adequately powered clinical trials on the
therapeutic effects of metformin that include prognosis and survival markers. At the time that
this book chapter was being written, there are six ongoing clinical trials specifically on
pancreatic cancer and metformin from the ClinicalTrials.gov website (Table 2).
8. Conclusions and perspectives
Metformin is an inexpensive and well-tolerated drug and its utility as a chemopreventive and/
or chemotherapeutic agent can be harnessed when we identify the drug’s target/s, optimal
dosage, and the correct patient sub-population who will benefit from metformin treatment.
Until then, metformin remains the most widely prescribed anti-diabetic drug in the world with
an unknown mechanism of action. In the era of targeted cancer therapy, one may cautiously
link gene mutations and oncogenes up and down-regulation to cancer and involve metabolic
phenotyping of the patient for better selection and truly personalized medicine.
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